LOW-VOLUME · FEMALE-LED
raloxifene Side Effects
raloxifene (also sold as Evista) is a LOW-VOLUME FAERS extract #447 of 524 by FAERS report count. Still opens on FEMALE-LED: 98% of sex-coded reports are female (2,091 F / 34 M).
Data updated 2026-05-15
- 2,311
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
raloxifene reporting skew - 98% of sex-coded reports are female (2,091 F / 34 M). Volume band LOW-VOLUME #447 of 524 by FAERS report count; caseload SIGNAL.
Thinner FAERS extract for raloxifene (Evista) (2,311 reports #447 of 524 by FAERS report count). 98% of sex-coded reports are female (2,091 F / 34 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2004–2025). Stamps SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
FATIGUE leads 143 of 2,311 reports
FEMALE-LED reporters · age peak 65-74
Female-led reporters (98% of sex-coded rows)
Age peak 65-74 (540 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (155 reports, 6.7%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 69 |
| CARDIO-RESPIRATORY ARREST | 9 |
| DYSPNOEA | 9 |
| PNEUMONIA | 9 |
| DIARRHOEA | 8 |
| ASTHENIA | 7 |
| COMPLETED SUICIDE | 7 |
| FATIGUE | 7 |
| ATRIAL FIBRILLATION | 6 |
| NAUSEA | 6 |
| RESPIRATORY FAILURE | 6 |
| SEPSIS | 6 |
| ANAEMIA | 5 |
| HEADACHE | 5 |
| PAIN | 5 |
| ASCITES | 4 |
| BACTERAEMIA | 4 |
| CARDIAC DISORDER | 4 |
| DEHYDRATION | 4 |
| DRUG-INDUCED LIVER INJURY | 4 |
Reactions in Hospitalization Reports
Hospitalization mid-share (632, 27.3%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| FALL | 44 |
| PNEUMONIA | 39 |
| DIARRHOEA | 32 |
| DYSPNOEA | 29 |
| NAUSEA | 27 |
| PULMONARY EMBOLISM | 25 |
| FATIGUE | 23 |
| DIZZINESS | 22 |
| URINARY TRACT INFECTION | 22 |
| ASTHENIA | 21 |
| PAIN | 21 |
| PYREXIA | 19 |
| BACK PAIN | 18 |
| DECREASED APPETITE | 18 |
| VOMITING | 18 |
| ABDOMINAL PAIN | 17 |
| ATRIAL FIBRILLATION | 17 |
| CONSTIPATION | 17 |
| COUGH | 17 |
How to read raloxifene FAERS figures (SIGNAL · DEATH-HEAVY · HOSP-MID)
FAERS holds 2,311 voluntary reports linked to raloxifene (Evista), 2004-2025. Death is listed on 155 (6.7%). Hospitalization appears on 632 (27.3%). Top co-reported indication: Product Used For Unknown Indication.
Sparse extract - named reactions and FEMALE-LED skew still differ by drug; not a complete safety profile.
Read with raloxifene
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 2,289 FAERS cases (Δ 22 lighter vs raloxifene); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 2,273 FAERS cases (Δ 38 lighter vs raloxifene); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 2,254 FAERS cases (Δ 57 lighter vs raloxifene); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 2,380 FAERS cases (Δ 69 heavier vs raloxifene); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 55.4 pp vs raloxifene's DEATH-HEAVY): CASELOAD · HOSP-MID.
raloxifene stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload SIGNAL and the label guide.